Digital Scrip Awards 2020
We are delighted to announce the 2020 Digital Scrip Awards winners!
We are delighted to announce the 2020 Digital Scrip Award Winners!. Click here to view the full winners list.
The Digital Scrip Awards took place on 2 December 2020 and acknowledged the outstanding achievements taking place across the industry. We’d like to thank everyone who entered, sponsored and attended the digital Scrip Awards, and congratulations to all our winners. We hope to be able to see you all in person in 2021!
If you would like to be kept up to date with Scrip Awards 2021 launch dates - please contact Jo Kirkpatrick on email@example.com
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. In the current climate it’s more important than ever to recognize what has been achieved. This year, we have introduced a new category – China Biopharma Leadership Award – to reflect the rapid maturing of China’s biopharma sector, thanks to the development of homegrown biopharma companies, CDMOs and increasing investment in the market from global multinational biopharma companies. Over the past 16 years, the Scrip Awards has carved out a unique place in the industry calendar, with attendees coming from around the world to the prestigious ceremony.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 94 locations in 40 countries and has approximately 15,150 employees.
Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. With hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations worldwide.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com.
Parexel partners with life science and biopharmaceutical customers across the globe to help transform scientific discoveries into innovative new therapies that improve patient health. Our full-service offerings span early phase to post-marketing approval and include expert consultation across regulatory and consulting, laboratory services, real-world evidence, market access and more. With more than 35 years of experience, our therapeutic, technical and functional abilities are underpinned by a deep conviction In what we do best: supporting our customers in fulfilling the unmet medical needs of patients worldwide.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."
AstraZeneca is responding to a changing world and an increasing burden of disease by advancing one of the strongest and most productive pipelines in our industry and working to deliver life-changing medicines to patients around the world. We are continuing to push the boundaries of science in search of solutions that prevent, treat, and even cure, some of the world’s most serious health challenges: cancer, diabetes, heart, kidney, respiratory and immunological diseases. Our focus is on driving growth by supplying medicines that can transform care and ensuring that they reach patients who need them in a way that brings wider benefits to society and the planet.
Our mission is to become a global leader in the discovery, development, and commercialization of innovative, molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity.
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.
Our global team of researchers and scientists, together with our partners, harness cutting-edge science to push the boundaries of what is possible in order to bring transformative, life-changing therapies to patients worldwide.
Takeda seeks to improve people's lives by researching, developing and bringing to market new and better medicines that help to address the nation's most pressing healthcare needs. We focus on the areas of oncology, gastroenterology and diabetes.